Skip to main content

Table 3 Toxicities by grade of severity, according to the CTCAE (version 4.03)

From: Retrospective analysis to evaluate the efficacy and the safety of Bevacizumab in the treatment of recurrent malignant gliomas

Chemotherapy-related toxicity

n (%)

Toxicity

Grade 1

Grade 2

Grade 3

Grade 4

Hypertension

6 (35.3)

2 (11.8)

Proteinuria

7 (41.2)

2 (11.8)

1 (5.9)

Thromboembolic event

1 (5.9)

Headache

4 (23.5)

Skin alteration

3 (17.6)

Hypotension

2 (11.8)

Thrombocytopenia

1 (5.9)

1 (5.9)

Leukopenia

2 (11.8)

4 (23.5)

Anemia

3 (17.6)

Hypertransaminasemia

5 (29.4)

Astenia

1 (5.9)

3 (17.6)